{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:10:43Z","timestamp":1768349443477,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ahj.2009.04.006","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T04:17:40Z","timestamp":1242620260000},"page":"S24-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events"],"prefix":"10.1016","volume":"157","author":[{"given":"Vasilios","family":"Papademetriou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2009.04.006_bib1","first-page":"469","article-title":"Prevalence of Stroke-US, 2008","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"10.1016\/j.ahj.2009.04.006_bib2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib5","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.288.15.1882","article-title":"Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program","volume":"288","author":"Whelton","year":"2002","journal-title":"JAMA"},{"issue":"1 Suppl","key":"10.1016\/j.ahj.2009.04.006_bib6","first-page":"I16","article-title":"Implications of the INTERSALT study","volume":"17","author":"Stamler","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2009.04.006_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib8","series-title":"Hypertension: pathophysiology, diagnosis and management","first-page":"127","article-title":"Impact of systolic and diastolic blood pressure on cardiovascular mortality","author":"Neaton","year":"1995"},{"key":"10.1016\/j.ahj.2009.04.006_bib9","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3317\/jraas.2006.012","article-title":"From hypertension to heart failure\u2014are there better primary prevention strategies?","volume":"7","author":"Meredith","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.ahj.2009.04.006_bib11","first-page":"45","article-title":"Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?","volume":"7","author":"Weber","year":"2006","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib12","article-title":"Blood Pressure Lowering Treatment Trialists' Collaboration\u2014second cycle of analyses","author":"MacMahon","year":"2003"},{"key":"10.1016\/j.ahj.2009.04.006_bib13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood-pressure\u2013lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively-designed overviews of randomised trials","volume":"165","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib14","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker or diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.280.13.1168","article-title":"Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"280","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib16","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11883-001-0047-2","article-title":"The renin angiotensin system as a risk factor for coronary artery disease","volume":"3","author":"Farmer","year":"2001","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2009.04.006_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2009.04.006_bib20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1524-6175.2007.06602.x","article-title":"The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications","volume":"9","author":"Chrysant","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ahj.2009.04.006_bib21","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC; National Heart, Lung, and Blood Institute. AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.006_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.jhh.1001960","article-title":"RAS inhibition in hypertension","volume":"20","author":"Ibrahim","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ahj.2009.04.006_bib23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0735-1097(99)00634-8","article-title":"The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)","volume":"35","author":"Kjoller-Hansen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.04.006_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure\u2013lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0735-1097(99)00146-1","article-title":"Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group","volume":"34","author":"Gustafsson","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.04.006_bib31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.006_bib32","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin converting enzyme inhibition in stable coronary artery disease","volume":"351","author":"The PEACE Trial Investigators","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.04.006_bib34","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1016\/S0002-8703(03)00443-5","article-title":"Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease","volume":"146","author":"Kondo","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2009.04.006_bib35","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.006_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2009.04.006_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08037050510008823","article-title":"The Study on COgnition and Prognosis in the Elderly (SCOPE) major CV events and stroke in subgroups of patients","volume":"14","author":"Trenkwalder","year":"2005","journal-title":"Blood Press"},{"key":"10.1016\/j.ahj.2009.04.006_bib38","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","article-title":"The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors","volume":"34","author":"Schrader","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2009.04.006_bib39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2009.04.006_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00004872-199005000-00001","article-title":"Isolated systolic hypertension in the elderly","volume":"8","author":"Staessen","year":"1990","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2009.04.006_bib41","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11906-000-0008-0","article-title":"Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?","volume":"2","author":"Franklin","year":"2000","journal-title":"Curr Hyp Reports"},{"key":"10.1016\/j.ahj.2009.04.006_bib43","first-page":"1175","article-title":"Study on COgnition and Prognosis in the Elderly study group: stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"44","author":"Papademetriou","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.04.006_bib44","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.006_bib45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jama.288.12.1491","article-title":"Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy","volume":"288","author":"Kjeldsen","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.006_bib46","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1524-6175.2005.04254.x","article-title":"The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study","volume":"7","author":"Kjeldsen","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ahj.2009.04.006_bib47","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/S0149-2918(03)80332-6","article-title":"A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study","volume":"25","author":"Malacco","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2009.04.006_bib48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0195-668X(03)95767-8","article-title":"Comparison of the effects of valsartan and amlodipine alone or combined with low-dose diuretic on ambulatory blood pressure in elderly patients with isolated systolic hypertension (Val-Syst Study) [abstract]","volume":"24","author":"Malacco","year":"2003","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2009.04.006_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/08038020310000122","article-title":"Valsartan\/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy","author":"Mallion","year":"2003","journal-title":"Blood Press"},{"key":"10.1016\/j.ahj.2009.04.006_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0002-9149(00)01490-9","article-title":"Efficacy and safety of losartan\/hydrochlorothiazide in patients with severe hypertension","volume":"87","author":"Oparil","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2009.04.006_bib51","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0149-2918(01)80101-6","article-title":"Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension","volume":"23","author":"Flack","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2009.04.006_bib52","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309002750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309002750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:38:38Z","timestamp":1757569118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870309002750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0002870309002750"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2009.04.006","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2009.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}